Long-term high-dose L-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial.
Davide MenafraCristina de AngelisFrancesco GarifalosM MazzellaGiacomo GaldieroMariangela PiscopoM CastoroNunzia VerdeClaudia PivonelloChiara SimeoliRenata Simona AuriemmaAnnamaria ColaoRosario PivonelloPublished in: Journal of endocrinological investigation (2022)
The results of the current study demonstrated that supplementation with relatively high doses of L-ARG as a single compound for 3 months significantly improved penile erectile function, assessed by both IIEF-6 score and PSV at dynamic PDU in patients with mild-moderate, and improved IIEF-6 score, but not PSV, in patients with severe vasculogenic ED, therefore suggesting that L-ARG might be an alternative treatment in mild-moderate vasculogenic ED patients experiencing adverse effects or with contraindications for chronic treatment with PDE5i compounds.
Keyphrases
- double blind
- placebo controlled
- clinical trial
- phase iii
- phase ii
- high dose
- study protocol
- emergency department
- end stage renal disease
- open label
- ejection fraction
- nitric oxide
- newly diagnosed
- prostate cancer
- randomized controlled trial
- high intensity
- squamous cell carcinoma
- early onset
- phase ii study
- stem cell transplantation
- peritoneal dialysis
- radical prostatectomy
- amino acid
- benign prostatic hyperplasia